Cognition Therapeutics Inc. Common Stock CGTX · Stock Open Cognition Therapeutics Inc. Common Stock in new tab
Cognition Therapeutics Inc. Common Stock Analysis (CGTX)
Is Cognition Therapeutics Inc. Common Stock a good investment? Cognition Therapeutics Inc. Common Stock (CGTX) is currently trading at 0.8912 USD. Market analysts have a consensus price target of 3.33 USD. This suggests a potential upside from current levels.
Earnings Schedule: Cognition Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -0.22.
Investor FAQ
Does Cognition Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Cognition Therapeutics Inc. Common Stock?
Cognition Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -0.17.
Company Profile
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Community Discussion